Abstract Number: 1290 • 2012 ACR/ARHP Annual Meeting
Effects of Tofacitinib On Lipid Profiles and Cholesterol and Lipoprotein Kinetics in Patients with Rheumatoid Arthritis
Background/Purpose: Tofacitinib is a novel oral Janus kinase inhibitor being investigated as a targeted immunomodulator and disease-modifying therapy for RA. In RA patients (pts), suppression…Abstract Number: L12 • 2012 ACR/ARHP Annual Meeting
Short- and Long-Term Efficacy of Tofacitinib, an Oral Janus Kinase Inhibitor, in the Treatment of Patients with Rheumatoid Arthritis and an Inadequate Response to TNF Inhibitors: Analyses of Pooled Phase 2, Phase 3, and Long-Term Extension Studies
Background/Purpose: Tofacitinib is a novel, oral Janus kinase inhibitor investigated as a targeted immunomodulator and disease-modifying therapy for rheumatoid arthritis (RA). The efficacy and safety…Abstract Number: 1833 • 2012 ACR/ARHP Annual Meeting
Healthcare Costs in Psoriatic Arthritis Patients Newly Initiated On a Biologic Disease-Modifying Anti-Rheumatic Drug or Methotrexate
Background/Purpose: Several treatment options are available for psoriatic arthritis (PsA) patients (pts). The healthcare cost associated with the management of PsA pts varies depending on…Abstract Number: 1242 • 2012 ACR/ARHP Annual Meeting
Use of Anti-Tumor Necrosis Factor Therapy Is Associated with Reduced Cardiovascular Event Risk in Rheumatoid Arthritis
Background/Purpose: Rheumatoid arthritis (RA) is associated with increased risks for cardiovascular (CV) comorbidities because of an increased prevalence of traditional CV risk factors and the…Abstract Number: 1836 • 2012 ACR/ARHP Annual Meeting
Early Versus Delayed Initiation of Disease-Modifying Antirheumatic Drugs in Rheumatoid Arthritis
Background/Purpose: Studies from a number of countries suggest that the time between symptom onset and initiation of DMARD therapy in RA patients is still longer…Abstract Number: 1215 • 2012 ACR/ARHP Annual Meeting
Rates of Orthopaedic Interventions for Rheumatoid Arthritis Have Changed Over the Last 25 Years. A Report From Two UK Inception Cohorts Reflecting Treatment Changes From Sequential DMARD Monotherapy to Anti-TNF Agents (1986-2011)
Background/Purpose: Orthopaedic surgery is considered an important, although uncommonly reported, outcome measure in rheumatoid arthritis (RA) and a surrogate marker for joint destruction. The expectation…Abstract Number: 1838 • 2012 ACR/ARHP Annual Meeting
10-Year Trends in the Use of Disease Modifying Anti-Rheumatic Drugs (DMARDs) and Biologic Agents in Rheumatoid Arthritis: A National Veteran Affairs Study
Background/Purpose: It is unclear how recommendations for disease modifying anti-rheumatic drugs (DMARDs) & biological agents in treatment of Rheumatoid Arthritis (RA) have influenced their use…Abstract Number: 1014 • 2012 ACR/ARHP Annual Meeting
Trimmed Analyses, a New Approach to the Analysis of Sharp Score Data in the Assessment of Progression in Patients with Rheumatoid Arthritis
Background/Purpose: Tofacitinib is a novel oral Janus kinase inhibitor being investigated as a targeted immunomodulator and disease-modifying therapy for RA. In the Phase 3 ORAL…Abstract Number: 2638 • 2012 ACR/ARHP Annual Meeting
Biologic Switching Among Patients with Rheumatoid Arthritis in the United States, 2004-2011
Background/Purpose: While studies have assessed the efficacy of switching among biologic disease-modifying antirheumatic drugs (bDMARD), there is a lack of knowledge regarding the patterns of…Abstract Number: 1697 • 2012 ACR/ARHP Annual Meeting
Meta-Analysis of Malignancies, Serious Infections, and Serious Adverse Events with Tofacitinib or Biologic Treatment in Rheumatoid Arthritis Clinical Trials
Background/Purpose: Patients with rheumatoid arthritis (RA) experience adverse events (AEs) attributed to both the disease and its treatment. Tofacitinib is a novel oral Janus kinase…Abstract Number: 928 • 2012 ACR/ARHP Annual Meeting
Is There an Optimal Treatment Strategy for Disease-Modifying-Antirheumatic-Drug Naïve Patients with Rheumatoid Arthritis?
Background/Purpose: There is a lack of head-to-head clinical trial data to determine the most effective treatment for rheumatoid arthritis (RA). However, these trials have had…Abstract Number: 2546 • 2012 ACR/ARHP Annual Meeting
Tofacitinib Inhibits Radiographic Progression in Patients with Rheumatoid Arthritis Prone to Develop Structural Damage: A Post-Hoc Analysis of a Phase 3 Trial
Background/Purpose: Tofacitinib is a novel, oral Janus kinase inhibitor being investigated as a targeted immunomodulator and disease-modifying therapy for RA. In the ORAL Scan trial…Abstract Number: 1669 • 2012 ACR/ARHP Annual Meeting
Infection Risk After Orthopaedic Surgery in Patients with Inflammatory Rheumatic Diseases, with Focus On Discontinuation of TNF-Alpha-Inhibitors
Background/Purpose: Infections after orthopaedic surgeries are feared complications, leading to costly treatments and successive interventions. A higher postoperative infection risk is discussed in patients with…Abstract Number: 833 • 2012 ACR/ARHP Annual Meeting
A Phase 1, Randomized, Double-Blind, Placebo-Controlled Multiple-Dose Study of Intravenous Staphylococcal Protein A in Patients with Active Rheumatoid Arthritis On Methotrexate: Safety, Pharmacokinetics and Efficacy
Background/Purpose: PRTX-100 is highly-purified GMP staphylococcal protein A (SpA) that binds with extremely high affinity to the Vh antibody framework region of Clade Vh3 immunoglobulins. …Abstract Number: 2545 • 2012 ACR/ARHP Annual Meeting
A Randomized, Double-Blind, Parallel Group Study of the Safety and Efficacy of Tocilizumab SC Versus Tocilizumab IV, in Combination with Traditional Dmards in Patients with Moderate to Severe RA
Background/Purpose: The objective of this study was to compare the efficacy and safety of tocilizumab (TCZ) subcutaneous (SC) and TCZ intravenous (IV) regimen in patients…
ACR Meeting Abstracts